1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ALK-Abelló A/S

ALK-Abelló A/S

ALK-B.CO
ALK-Abelló A/SDK flagNASDAQ Copenhagen
243.60
DKK
+2.60
- -
53.98BMarket Cap
ALK-Abelló A/S
ALK-B.CO
(NASDAQ Copenhagen)

Recent

price

243.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.89
11.86
12.03
11.61
12.59
13.24
15.31
14.67
13.41
15.03
15.99
17.85
20.46
21.81
25.02
28.49
29.73
Revenue per Share
0.65
1.01
1.07
0.32
0.94
1.77
1.38
-0.8
-0.78
-0.23
0.11
1
1.52
2.2
3.68
5.4
5.8
Basic EPS, GAAP
0.57
1.4
-0.78
-0.55
0.61
-0.08
0.92
-3.3
-1.26
-0.16
0.36
0.93
0.29
1.3
-0.41
6.58
8.14
Free Cash Flow per Basic Share
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25
- -
- -
- -
- -
- -
- -
- -
- -
1.61
Dividend per Share
10.23
10.97
11.63
11.78
12.1
13.82
14.53
17.02
14.82
14.67
15.01
16.05
18
20.19
23.98
27.96
30.07
Book Value per Share
7.12
7.8
8.25
8.15
8.75
9.99
10.75
12.79
11.29
11.45
11.58
13.03
15.17
17.07
16.18
21.13
21.67
Tangible Book Value per Share
198
198
195
193
193
194
196
198
217
218
218
219
221
221
221
222
221
Basic Weighted Avg Shares
2,159
2,348
2,345
2,244
2,433
2,569
3,005
2,910
2,915
3,274
3,491
3,916
4,511
4,824
5,537
6,312
6,561
Sales/Revenue/Turnover
8.89
12.73
7.76
5.84
12.86
11.41
15.94
-2.75
-3.29
-0.92
4.3
7.46
10.42
13.81
19.7
26.2
26.75
Operating Margin (%)
95
107
124
127
140
159
163
333
232
255
245
242
238
245
272
328
341
Depreciation Expense
128
200
209
61
181
344
270
-158
-170
-50
25
219
335
486
815
1,197
1,280
Net Income, GAAP
38.16
37.69
52.21
41.35
39.67
14
44.56
- -
- -
- -
75.25
21.51
25.06
24.88
22.89
26.79
26.65
Effective Tax Rate (%)
5.93
8.52
8.91
2.72
7.44
13.39
8.99
-5.43
-5.83
-1.53
0.72
5.59
7.43
10.07
14.72
18.96
19.51
Profit Margin (%)
419
795
644
527
508
617
1,144
1,489
1,273
1,314
1,311
1,018
1,246
1,654
1,345
3,165
3,231
Working Capital
37
330
327
322
319
328
758
741
725
941
893
429
429
439
451
355
349
LT Debt
2,018
2,163
2,257
2,249
2,354
2,697
2,875
3,290
3,179
3,176
3,153
3,480
3,988
4,447
5,373
6,445
6,569
Total Equity
5.74
7.95
3.36
2.93
7.08
8.24
7.37
- -
- -
- -
0.88
5.39
7.78
9.92
13.89
17.48
18.82
Return on Invested Capital (%)
11.85
8.95
8.4
2.59
7.13
11.89
7.99
- -
- -
- -
0.8
5.61
7.94
10.16
14.76
18.61
18.95
Return on Capital (%)
12.02
9.52
9.42
2.69
7.85
13.7
9.75
-5.07
-5.15
-1.56
0.77
6.44
8.95
11.53
16.68
20.82
20.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
65
63
61
LT Borrowings
155
151
147
LT Finance Leases
244
204
202
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
222
222
222
Market Capitalization
46,175
50,650
44,616

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3,648
4,494
4,665
Cash, Cash Equivalents & STI
666
1,240
1,545
Accounts Receivable, Net
1,050
1,093
1,048
Inventories
1,734
1,783
1,787
Total Current Liabilities
1,423
1,329
1,434
Payables & Accruals
- -
- -
- -
ST Debt
65
63
61
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.41%
15.45%
19.95%
Free Cash Flow
-356.23%
-280.56%
-1,718.89%
Net Income, GAAP
59.56%
197.72%
46.87%
Sales/Revenue/Turnover
9.6%
12.62%
14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,351
1,374
1,313
1,499
5,537
2025
1,522
1,527
1,530
1,733
6,312
2026
1,771
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.1
0.9
1
- -
3.68
2025
1.6
1.2
1.4
- -
5.4
2026
2
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
1.62
- -
- -
- -
- -
Similar Companies
Legend Biotech Corporation (LEGN)
Inhibrx Biosciences Inc. (INBX)
OptiBiotix Health Plc (OPTI.L)
eFFECTOR Therapeutics, Inc. (EFTR)
Pharma Mar, S.A. (0RC6.L)
SYBLEU Inc (SYBE)
Business
ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of allergy immunotherapy (AIT) products for the prevention and treatment of allergic diseases. The company’s core product portfolio includes sublingual immunotherapy tablets (SLIT-tablets) for allergies such as grass pollen (GRAZAX/GRASTEK), ragweed pollen (RAGWITEK), and house dust mite (ACARIZAX/ITULATEK), as well as subcutaneous immunotherapy (SCIT) allergy vaccines targeting a broad spectrum of allergens including pollens, molds, mites, pets, bees, and wasps. ALK also offers emergency treatments such as adrenaline autoinjectors for anaphylaxis management, allergy diagnostic kits including skin prick tests, and bulk allergen extracts primarily marketed to allergy specialists in the United States. Operating globally with presence in 46 countries across Europe, North America, and Asia-Pacific, the company manufactures products at facilities in Denmark, France, Spain, and the United States. Founded in 1923 and headquartered in Hørsholm, Denmark, ALK is one of the leading global providers in allergy immunotherapy. In recent years, ALK has focused on expanding its pipeline of patient-friendly allergy treatments, notably advancing its portfolio of SLIT-tablets and pursuing strategic collaborations including a 2024 global licensing deal to commercialize the neffy® adrenaline nasal spray (excluding the USA, Australia, New Zealand, Japan, and China) with U.S.-based ARS Pharmaceuticals, enhancing its emergency treatment offerings. Furthermore, in 2025 ALK entered a partnership with Changchun GeneScience Pharmaceutical Co. (GenSci) to expand the market for its house dust mite allergy immunotherapy products in China, aiming to accelerate commercial uptake and innovation collaboration across allergic diseases between the companies for China and international markets. ALK also recently expanded its Executive Leadership Team to support its growth strategy and commercial execution across key global markets. These initiatives complement ALK’s ongoing commitment to research and development, driving innovation in allergy care and expanding access to its immunotherapy treatments globally.

Company News

APIChatGPT

  • globenewswire.com

    Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight